Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive
Xeris Biopharma Holdings, Inc. is an overlooked specialty pharmaceutical company with three FDA-approved products, utilizing its proprietary XeriSol and XeriJect technologies to develop innovative injectable drug formulations. Gvoke and Recorlev drive Xeris' rapid growth, with Gvoke holding 34% of the retail glucagon market and Recorlev expanding its patient base by 124%. Xeris' strategic partnerships and promising pipeline, particularly XP-8121 for hypothyroidism, offer strong potential for value creation and long-term growth.
Xeris Biopharma: Time For A Reassessment
Xeris Biopharma is trading above my Buy Threshold of $2.76 and is nearing a potential breakout above the $3.25 resistance level. The company shows strong revenue growth, driven by products like Gvoke and Recorlev, despite not yet reporting a positive EPS. Risks include intense competition and potential need for additional funding, but projected revenue growth suggests significant upside potential.
Xeris Biopharma Holdings, Inc. (XERS) Q2 2024 Earnings Call Transcript
Start Time: 08:30 January 1, 0000 9:03 AM ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q2 2024 Earnings Conference Call August 08, 2024, 08:30 AM ET Company Participants John Shannon - CEO Steven Pieper - CFO Allison Wey - SVP, IR and Corporate Communications Conference Call Participants Roanna Ruiz - Leerink Partners Chase Knickerbocker - Craig-Hallum Rohan Mathur - Oppenheimer Operator Hello, everyone, and welcome to today's Xeris Biopharma Second Quarter 2024 Financial Results Call. My name is Drew, and I'll be your operator today.
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
Xeris Biopharma (XERS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.14 per share a year ago.
Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should Know
Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy?
From a technical perspective, Xeris Biopharma Holdings, Inc. (XERS) is looking like an interesting pick, as it just reached a key level of support. XERS's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
Xeris Biopharma unveils CEO succession plan, John Shannon to lead company
Xeris Biopharma Holdings (NASDAQ:XERS) announced a CEO succession plan with John Shannon taking over from Paul Edick on August 1, 2024. Edick, the current CEO and chairman, will retire from his roles after more than seven years with the company.
